Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ANNX vs OLMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OLMA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 2–3 Matrix Metrics)

OLMA Overall Winner 6-Pillar Tally: ANNX 2 – 2 OLMA (2 Tie) Matrix Metrics: ANNX 3 – 2 OLMA

As of Nov 17, 2026, Olema Pharmaceuticals, Inc. (OLMA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin), whereas OLMA carries 43.8/100 (HOLD) at $7.15 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile OLMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANNX vs OLMA
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.69β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98
OLMA NASDAQ Head-to-Head Winner
Olema Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$7.15
-2.85% 1D
Market Cap $662.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.81β · 83% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 39.0 Fund 55.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 45
RSI-14: 44.8 · SMA20: $7.21 · SMA50: $8.04

6-Pillar Scorecard Institutional Category Breakdown (ANNX 2 – 2 OLMA)

Columns: Metric · ANNX · OLMA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ANNX
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $747.8M $662.3M
3. Profitability & Quality OLMA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -130.8% -69.8%
4. Balance Sheet & Cash Flow OLMA
Cash Generation (TTM) -$190M -$178M
Cash Flow Margin N/A N/A
Net Cash / Leverage $29M Net Cash $44M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 569.3% (100th %ile) 164.8% (18th %ile)
Put/Call OI Skew 0.09x (Call-Skewed) 18.47x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANNX (3) vs OLMA (2)
Institutional Metric ANNX OLMA Criterion Row Edge
Market Capitalization
Scale
$747.8M $662.3M Larger Scale ANNX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-130.8% -69.8% Higher ROE OLMA
52-Week Range Position
Momentum
18% ($3–$7) 3% ($6–$36) Stronger Trend ANNX
Beta / 30D Volatility
Risk Regime
1.69β · 63% Vol 1.81β · 83% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite OLMA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$190M ($29M Net Cash) -$178M ($44M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OLMA +13.65 pp
ANNX: -13.09% · OLMA: +0.56%
3M Horizon ANNX +0.14 pp
ANNX: -36.64% · OLMA: -36.78%
6M Horizon ANNX +16.4 pp
ANNX: -29.02% · OLMA: -45.42%
1Y Horizon ANNX +43.48 pp
ANNX: +28.6% · OLMA: -14.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs OLMA. Trailing 12-month operating profitability (ANNX 0.0% vs OLMA 0.0%) and valuation multiples (ANNX N/M vs OLMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M
OLMA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OLMA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 164.8%
IV Percentile 18th %ile
Put/Call OI Skew 18.47x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OLMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OLMA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $662.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANNX vs OLMA Key Questions & Quantitative Answers

As of Nov 17, 2026, Olema Pharmaceuticals, Inc. (OLMA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin), whereas OLMA carries 43.8/100 (HOLD) at $7.15 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile OLMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANNX leads the Growth & Scale pillar: ANNX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OLMA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANNX generates N/A in USD-normalized revenue versus N/A for OLMA. In operating R&D and SG&A reinvestment, ANNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OLMA.

ANNX and OLMA trade at balanced relative valuation multiples. ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OLMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANNX (-130.8% ROE) versus OLMA (-69.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 63% Vol realized risk). By comparison, OLMA carries 164.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 18.47x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 83% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.